PTH(1–34) for Surgical Hypoparathyroidism: A 2-Year Prospective, Open-Label Investigation of Efficacy and Quality of Life

• DOI: 10.1210/jc.2017-01555
• Publication Date: 2017-11-01T17:59:56Z
• Authors: Andrea Palermo; Assunta Santonati; Gaia Tabacco; Daniela Bosco; Antonio Spada; Claudio Pedone; Bruno Raggiunti; Tina Doris; Daria Maggi; Franco Grimaldi; Silvia Manfrini; Fabio Vescini
• Keywords: Hypoparathyroidism; Open label

ContextDaily parathyroid hormone (PTH) (1–34) administrations can reduce the required total daily dose of calcium and calcitriol restore normocalcemia in refractory hypoparathyroidism. However, most PTH(1–34) trials have been conducted on small cohorts including subjects with hypoparathyroidism various etiologies, quality life (QOL) was not investigated.